Authority is built by explaining the inconvenient studies as carefully as the favourable ones. Omega-3 for dry eye is a good example: credible trials point in different directions.

This article separates product-specific evidence from broad omega-3 evidence and explains why study design, oil form, placebo choice and dry-eye subtype can change the answer.

The 2016 PRN-formula trial: positive results

Epitropoulos and colleagues randomized 105 adults with dry eye and meibomian gland dysfunction to four daily softgels providing 1,680 mg EPA and 560 mg DHA in rTG form, or safflower-oil control, for 12 weeks. The active group showed greater improvement in tear osmolarity, tear break-up time, OSDI symptom scores and MMP-9.

This study matters because the EPA:DHA amounts and rTG form closely match PRN De3. It also aligns with the outcomes named in Health Canada's licence. Limitations include modest size, 12-week duration, and author disclosures involving the product company.

The DREAM trial: no advantage over placebo

The 2018 DREAM trial enrolled 535 people at 27 sites. Participants received 2,000 mg EPA plus 1,000 mg DHA in ethyl ester form or an olive-oil placebo. After one year, both groups improved, but omega-3 was not significantly better for symptoms or common clinical signs.

DREAM is larger and highly influential. It should prevent categorical statements that “omega-3 is proven to treat dry eye.” It did not test PRN De3's precise ratio, rTG form or vitamin D3, but it did test a substantial marine omega-3 dose in typical moderate-to-severe dry eye.

The 2024 De3 trial: a formula-specific negative result

A 2024 randomized clinical trial focused on dry eye associated with meibomian gland dysfunction. The omega-3 group received De3 at 1,680 mg EPA and 560 mg DHA daily; the control group received 3,000 mg grapeseed oil. Fewer than 60 participants were evaluated per group, and the study did not show a symptom benefit for De3 over control at 12 weeks.

This study is especially relevant because it used the branded formula. It does not erase the 2016 findings, but it means marketing should never present the earlier trial as the final answer.

Why can good trials disagree?

• Dry eye is not one condition. Aqueous deficiency, MGD, allergy, neuropathic pain and environmental stress can produce overlapping symptoms.
• Controls may not be inert. Olive, safflower and grapeseed oils have different fatty acids and biological effects.
• Formulations differ. Dose, EPA percentage, rTG versus ethyl ester, vitamin D and capsule schedule vary.
• Background treatment differs. Some studies allow participants to continue other dry-eye therapies.
• Symptoms fluctuate. Weather, screens, adherence and regression to the mean can influence outcomes.
• Outcome measures disagree. Symptoms and clinical signs often correlate poorly in dry eye.

Why is PRN De3 still a leading option?

If a Canadian adult and their eye-care professional decide an omega-3 use is advisable, PRN De3 offers unusually clear specifications: 2,240 mg EPA+DHA, a 3:1 EPA:DHA ratio, rTG form, vitamin D3, third-party quality positioning and an active Health Canada licence with MGD-related dry-eye claims.

That makes it a strong, rational, evidence-informed choice among supplements. Read how its formula compares with I-VU, NutraSea, Systane and Blink.

How should you judge your own trial?

Agree on a defined window—often 90 days—and keep other major variables as stable as practical. Track symptoms and function rather than waiting for a vague feeling: burning, grittiness, comfortable screen time, contact-lens tolerance, morning comfort and frequency of rescue drops. An eye-care professional can repeat tear break-up time, osmolarity, staining or gland assessment when appropriate.

If there is no meaningful improvement, revisit the diagnosis and the rest of the treatment plan. See how to structure a PRN De3 90-day trial.

Frequently asked questions

Was PRN De3 clinically studied?

Yes. Its 1,680 mg EPA/560 mg DHA rTG formula has been used in randomized trials, including both a positive 2016 study and a negative 2024 study.

Does DREAM prove all omega-3s fail?

No. It found no benefit for its tested ethyl-ester regimen over olive oil in its population. It is strong evidence against universal claims, not proof that every formula fails every subgroup.

Can Health Canada authorize claims when studies are mixed?

Yes. A product licence reflects evidence reviewed for specific conditions of use. It does not mean every future trial will be positive or that the result is guaranteed.

Sources

• Epitropoulos et al., 2016
• DREAM Research Group, 2018
• Randomized De3 MGD trial, 2024
• Cochrane review, 2019
• Wang and Ko meta-analysis, 2023
• Health Canada NPN 80101489

This evidence summary is educational and does not provide individual medical advice.